V. D. Dodge, E. M. Cox
Dodge & Cox Stock Fund
Dodge & Cox Stock Fund Portfolio 13F
Dodge & Cox Stock Fund Holdings Activity
- Portfolio value:
- $81.11B≈ (+$10B≈)
- Previous value:
- $70.71B≈
- # of changes:
- 65
- New positions:
- 2
- Reported for:
- 31 Mar 2021 (Q1)
- Latest filing date:
- 28 May 2021
Dodge & Cox Stock Fund has disclosed a total of 65 changes to the portfolio in the (2021 Q1) SEC report(s): increased the number of shares of 24, bought 2 totally new, decreased the number of shares of 35 and completely sold out 4 position(s).
What stocks did Dodge & Cox Stock Fund buy in 2021 Q1?
During 2021 Q1 Dodge & Cox Stock Fund has bought 26 securities out of which top 5 purchases (by % change to portfolio) were (CMCSA) Comcast Corp (added shares +6.56%), (SNY) Sanofi ADR (added shares +81.49%), (GSK) GlaxoSmithKline PLC ADR (added shares +40.46%), (DELL) Dell Technologies Inc (added shares +3.50%) and (CHTR) Charter Communications Inc (added shares +20.59%).
What did Dodge & Cox Stock Fund invest in during 2021 Q1?
65 results
| History | Ticker | Name |
% or activity |
Shares change |
Shares held after* |
% change to portfolio |
Reported price* |
% difference current price* |
% of portfolio |
Held since* | Held for* |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ConocoPhillips
|
new
|
+14,874,758
|
14,874,758
|
+0.97%
|
$52.97
|
+124.58%($118.96)
|
0.97%
|
2021 Q1
|
≈ 0.25 years
|
|
|
|
Honda Motor Co Ltd ADR
|
new
|
+7,170,982
|
7,170,982
|
+0.27%
|
$30.20
|
-1.72%($29.68)
|
0.27%
|
2021 Q1
|
≈ 0.25 years
|
|
|
|
Fiserv, Inc
|
+135.63%
|
+5,550,700
|
9,643,200
|
+0.81%
|
$119.04
|
-54.32%($54.38)
|
1.42%
|
2020 Q4
|
≈ 0.50 years
|
|
|
|
Roche Holding Ltd ADR
|
+100.73%
|
+11,104,000
|
22,126,999
|
+0.56%
|
$40.56
|
|
1.11%
|
2019 Q3
|
≈ 1.75 years
|
|
|
|
Sanofi ADR
|
+81.49%
|
+20,592,007
|
45,862,828
|
+1.26%
|
$49.46
|
-13.47%($42.80)
|
2.80%
|
2019 Q3
|
≈ 1.75 years
|
|
|
|
Williams Companies Inc
|
+46.77%
|
+14,412,428
|
45,230,928
|
+0.42%
|
$23.69
|
+197.53%($70.48)
|
1.32%
|
2020 Q2
|
≈ 1.00 year
|
|
|
|
GlaxoSmithKline PLC ADR
|
+40.46%
|
+13,417,940
|
46,582,100
|
+0.74%
|
$44.61
|
+14.92%($51.27)
|
2.56%
|
2019 Q3
|
≈ 1.75 years
|
|
|
|
Biomarin Pharmaceutical Inc
|
+21.31%
|
+1,177,158
|
6,701,283
|
+0.11%
|
$75.51
|
-20.61%($59.94)
|
0.62%
|
2019 Q4
|
≈ 1.50 years
|
|
|
|
Charter Communications Inc
|
+20.59%
|
+535,100
|
3,134,286
|
+0.41%
|
$617.02
|
-76.74%($143.53)
|
2.38%
|
2019 Q3
|
≈ 1.75 years
|
|
|
|
Incyte Corp
|
+18.04%
|
+394,053
|
2,578,553
|
+0.04%
|
$81.27
|
+46.27%($118.88)
|
0.26%
|
2019 Q3
|
≈ 1.75 years
|
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
* Current price: this can be a delayed price and may not reflect the real-time market value, however it is too close.
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* Held since / Held for: calculated since the latest "new buy" position. If the security was previously exited and re-entered, only the most recent holding period is counted.